180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,000 shares of the company’s stock, valued at approximately $34,000.
Analyst Ratings Changes
Separately, Raymond James upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, May 22nd.
Check Out Our Latest Report on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Price Performance
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- P/E Ratio Calculation: How to Assess Stocks
- Jeff Brown’s Exegesis AI Stock Picks
- What is the Euro STOXX 50 Index?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.